An unusual ligand coordination gives rise to a new family of rhodium metalloinsertors with improved selectivity and potency.

Permalink
https://escholarship.org/uc/item/38h2r7s5

Journal
Journal of the American Chemical Society, 136(40)

ISSN
0002-7863

Authors
Komor, Alexis C
Barton, Jacqueline K

Publication Date
2014-10-01

DOI
10.1021/ja5072064

Peer reviewed
An Unusual Ligand Coordination Gives Rise to a New Family of Rhodium Metalloinsertors with Improved Selectivity and Potency

Alexis C. Komor and Jacqueline K. Barton*

Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena California 91125, United States

Supporting Information

ABSTRACT: Rhodium metalloinsertors are octahedral complexes that bind DNA mismatches with high affinity and specificity and exhibit unique cell-selective cytotoxicity, targeting mismatch repair (MMR)-deficient cells over MMR-proficient cells. Here we describe a new generation of metalloinsertors with enhanced biological potency and selectivity, in which the complexes show Rh−O coordination. In particular, it has been found that both Δ- and Λ-[Rh(chrysi)(phen)(DPE)]2+ (where chrysi = 5,6 chrysenequinone diimmine, phen = 1,10-phenanthroline, and DPE = 1,1-di(pyridine-2-yl)ethan-1-ol) bind to DNA containing a single CC mismatch with similar affinities and without racemization. This is in direct contrast with previous metalloinsertors and suggests a possible different binding disposition for these complexes in the mismatch site. We ascribe this difference to the higher pKₐ of the coordinated immine of the chrysi ligand in these complexes, so that the complexes must insert into the DNA helix with the inserting ligand in a buckled orientation; spectroscopic studies in the presence and absence of DNA along with the crystal structure of the complex without DNA support this assignment. Remarkably, all members of this new family of compounds have significantly increased potency in a range of cellular assays; indeed, all are more potent than cisplatin and N-methyl-N-nitro-nitrosoguanidine (MNNG, a common DNA-alkylating chemotherapeutic agent). Moreover, the activities of the new metalloinsertors are coupled with high levels of selective cytotoxicity for MMR-deficient versus proficient colorectal cancer cells.

INTRODUCTION

Since the successful application of cisplatin (cis-diaminedichloroplatinum) as an anticancer drug, the field of inorganic medicinal chemistry has undergone a revolution.1–4 For many years, the field focused on the development of more potent analogues (second- and third-generation derivatives), leading to the FDA approval of two additional cis-platinum(II) complexes, carboplatin and oxaliplatin.5 Cisplatin and carboplatin, in particular, have been highly successful in the treatment of a variety of cancers, including testicular, ovarian, cervical, and non-small cell lung cancers.6 However, these treatments are often associated with severe side effects and a buildup of resistance. These issues have led to a shift in the design of chemotherapeutics; researchers have begun to focus on a new design strategy where the chemotherapeutic interacts with a specific biological target found predominantly in cancer cells.7 The proposed mechanism of action of classical platinum-based chemotherapeutics is the formation of covalent DNA adducts, followed by cellular processing of these lesions, ultimately leading to apoptosis.6 The synthesis of new-generation classical therapeutics with enhanced DNA-binding properties in order to increase cytotoxicity has been extensively explored. However, the design and synthesis of therapeutics which bind to specific DNA lesions that are more prevalent in cancer cells than healthy cells may represent a targeted strategy for new chemotherapy. In particular, our laboratory has focused on the development of rhodium metalloinsertors (Figure 1), which bind mismatches in duplex DNA with high specificity, preferentially targeting thermodynamically destabilized mismatches over matched base pairs by a factor of over 1000.8,9 The binding mode of these complexes to mismatched DNA was subsequently crystallographically determined; the wide aromatic chrysi (chrysi = 5,6 chrysenequinone diimmine) ligand inserts into the DNA from the minor groove and ejects both mismatched bases in a binding mode termed metal-insertion.10,11 Ejection of the mismatched bases results in a large lesion that we have suggested may serve as a unique target within the cell.

Mismatches in genomic DNA arise naturally as a consequence of replication, but, if left uncorrected, can lead to mutations.12,13 The mismatch repair (MMR) pathway serves as a checkpoint to increase the fidelity of DNA replication ~1000 fold.14 Importantly, deficiencies in the mismatch repair machinery have been associated with several types of cancer as well as increased resistance to classical chemotherapeutics such as cisplatin as well as commonly used DNA-alkylating therapeutics.15 Therefore, the development of a targeted therapy for MMR-deficient cancers would be invaluable in the clinic. Due to the unique DNA mismatch-binding...
properties of rhodium metalloinsertors and the structural perturbation to DNA, their biological properties in MMR-deficient cells were investigated. The compounds have been found to inhibit growth and induce necrosis selectively in MMR-deficient colorectal cancer cells over MMR-proficient cells.\textsuperscript{16,17}

Recently in our laboratory, a family of 10 metalloinsertors with varying lipophilicities yet similar mismatch binding affinities was synthesized. Their abilities to preferentially target MMR-deficient cells over MMR-proficient cells was found to vary dramatically.\textsuperscript{18} One metalloinsertor in particular, [Rh(chrysi)(phen)(DPE)]\textsuperscript{2+} (Figure 1, DPE = 1,1-di-pyridine-2-yl)ethan-1-ol), was found to possess enhanced potency and selectivity compared to the others. Crystallization of the compound revealed the solid-state structure shown in Figure 2; the DPE ligand was discovered to coordinate to the rhodium center via one pyridine ring and the alcohol oxygen, in contrast to all other previously reported metalloinsertors, which coordinate via two pyridine nitrogens (Figure S2). It was hypothesized that this new ligand coordination environment was responsible for the enhanced biological activity of this compound, and we thus sought to synthesize a family of compounds inspired by this new ligand scaffold.

In this report, we describe the discovery of an unusual ligand coordination for the rhodium metalloinsertor [Rh(chrysi)-(phen)(DPE)]\textsuperscript{2+} and subsequent development of a family of compounds based on this new type of coordination environment. The entire family of compounds has been found to possess enhanced potency and cell selectivity in our cellular assays. In fact, all compounds studied are more potent than the FDA-approved chemotherapeutic cisplatin. All compounds have binding affinities for CC mismatches that range from 2.6 to 5.5 × 10\textsuperscript{6} M\textsuperscript{−1}, comparable to previous metalloinsertors. However, the amount of intracellular rhodium required for optimal biological activity for this family of compounds is more than five times lower than that of previously reported metalloinsertors, thus making them potent in the nanomolar concentration range. Importantly, all of the complexes exhibit a highly selective cytotoxicity for cells that are deficient versus proficient in MMR.


\section*{EXPERIMENTAL SECTION}

\textbf{Materials.} Commercially available chemicals were used as received. All organic reagents and Sephadex ion-exchange resin were obtained from Sigma-Aldrich unless otherwise noted. Sep-pak C\textsubscript{18} solid-phase extraction (SPE) cartridges were purchased from Waters Chemical Co. (Milford, MA). Media and supplements were purchased from Invitrogen (Carlsbad, CA). Bromodeoxyuridine (BrdU), antibodies, buffers, peroxidase substrate, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and acidified lysis buffer (10% SDS in 10 mM HCl) solution were purchased in kit format from Roche Molecular biochemistry (Mannheim, Germany).

\textbf{Oligonucleotide Synthesis and Purification.} Oligonucleotides were synthesized using standard phosphoramidite chemistry at IDT DNA (Coralville, IA) and purified by HPLC using a C\textsubscript{18} reverse-phase column (Varian, Inc.) on a Hewlett-Packard 1100 HPLC. Quantification was performed on a Cary 100 Bio UV–vis spectrophotometer using extinction coefficients at 260 nm (\(\epsilon_{260}\)) estimated for single-stranded DNA.

\textbf{Synthesis and Characterization of Ligands and Metal Complexes.} The complexes [Rh(bpy)\textsubscript{3}(chrysi)]\textsuperscript{3+} and [Rh(HDIPA)\textsubscript{2}(chrysi)]\textsuperscript{3+} were prepared according to published procedures.\textsuperscript{19,20} [Rh(chrysi)(phen)(NH\textsubscript{3})\textsubscript{2}]Cl\textsubscript{3} was prepared according to published procedures,\textsuperscript{19} and [Rh(HDIPA)\textsubscript{2}(phen)]Cl\textsubscript{2} was prepared. A 1 L round-bottomed flask was charged with [Rh(HDIPA)\textsubscript{2}(phen)][OT\textsubscript{3}][0.500 g, 0.626 mmol], chrysene-5,6-dione (0.162 g, 0.626 mmol), and 1:9 H\textsubscript{2}O:MeCN was added (400 mL). A 1 M solution of NaOH (1.5 mL) was added to the orange solution. Over the next hour, the solution changed color from orange to red, after which time a 1 M solution of HCl (1.5 mL) was added to quench the reaction. The MeCN was evaporated in vacuo, and the resulting red solution was loaded onto a SPE cartridge, eluted with 25% acetonitrile in 0.1% TFA, and lyophilized to give a red solid. The chloride salt can be obtained from a Sephadex QAE anion exchange column equilibrated with 0.1 M MgCl\textsubscript{2}. Yield: 0.536 g, 94%.

\textbf{EXPERIMENTAL SECTION}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{Chemical structures of metalloinsertors and binding affinities for oligonucleotides containing CC mismatches. All DNA binding affinities were measured in 100 mM NaCl, 20 mM Na\textsubscript{2}Pi, pH 7.1 buffer on the duplex 36-mer with the sequence 5′GGC ATG CAG ATTA CGA CTA CTA GGA TTC ACT GTC ATG-3′ (underline denotes the mismatch) in a competition assay through photocleavage by [Rh(bpy)\textsubscript{3},chrysi].\textsuperscript{15} Samples were irradiated and electrophoresed through a 20% denaturing PAGE gel, and the percent of DNA cleavage at each concentration was plotted as a function of log [Rhl]. The data were fitted to a sigmoidal curve, and \(K_B\) values were determined by calculating the concentration of rhodium at the inflection points of the curve and solving simultaneous equilibria.}
\end{figure}
resulting yellow solution was allowed to stir at −78 °C for 1 h and then warmed to ambient temperature. Next, saturated NH4Cl (aq) (30 mL) was added to quench the reaction, and the resulting solution was extracted with EtOAc (3 × 75 mL) and dried over Na2SO4 and the solvent evaporated in vacuo. The crude product was purified via flash chromatography (SiO2, 1:1 EtOAc:CH2Cl2 for L = Me and hexyl, 1:3 EtOAc:CH2Cl2 for L = Ph) to afford a light-yellow oil.

1,1-Di(pyridine-2-yl)ethan-1-ol (DPE). Yield: 100%. 1H NMR (CDCl3, 300 MHz): δ 8.57 (d, J = 5.1 Hz, 2H); 7.92 (d, J = 6.9 Hz, 2H); 7.80 (m, 2H); 7.27 (m, 2H); 6.60 (s, 1H); 2.08 (s, 3H). ESI-MS (cation): m/z calcd, 201.09 (M + H+); obs., 201.0. 

1-Phenyl-1-(pyridine-2-yl)ethan-1-ol (PPE). Yield: 55%. 1H NMR (CDCl3, 300 MHz): δ 8.52 (d of m, J = 5.1 Hz, 1 H); 7.65 (t of d, J = 7.8 Hz, 1.8 Hz, 1 H); 7.48 (m, 2H); 7.31 (m, 3H); 7.17–7.26 (m, 2H); 5.85 (s, 1H); 1.94 (s, 3H).

2-(Pyridine-2-yl)propan-2-ol (PPO). Yield: 35%. 1H NMR (CDCl3, 300 MHz): δ 8.51 (d of m, J = 6.0 Hz, 1H); 7.71 (t of m, J = 7.8 Hz, 1H); 7.38 (d of m, J = 8.1 Hz, 1H); 7.21 (t of m, J = 6.2 Hz, 1H); 5.08 (s, 1H); 1.54 (s, 6H).

2-(Pyridine-2-yl)octan-2-ol (PyOctanol). Yield: 80%. 1H NMR (CDCl3, 300 MHz): δ 8.51 (d of m, J = 6.0 Hz, 1H); 7.71 (t of m, J = 7.8 Hz, 1H); 7.32 (d of m, J = 9.0 Hz, 1H); 7.20 (t of m, J = 6.0 Hz, 1H); 5.18 (s, 1H); 1.78 (m, 2H); 1.51 (s, 3H); 1.19 (m, 6H); 0.82 (m, 6H).

According to an adaptation of a previously described method,18 [Rh(chrysi)(phen)(L)]Cl2 (L = DPE, PPE, PPO, PyOctanol) were synthesized. 

Figure 2. Structure of a new metalloinsertor, illustrating the coordination and ligand buckling. Left: X-ray crystal structure of [Rh(chrysi)(phen)(DPE)]Cl2. Displacement of ellipsoids is drawn at 50% probability. For clarity, chloride and hydrogen atoms (except imine protons) have been omitted. Top right: Side view. Note the severe distortion of the planarity of the chrysi ligand. Bottom right: View showing the steric clash responsible for the buckling of the chrysi ligand. Both hydrogens are shown as van der Waals surfaces.

1H NMR (CDCl3, 300 MHz): δ 8.52 (d of m, J = 5.1 Hz, 1H); 7.80 (m, 2H); 7.27 (m, 2H); 6.60 (s, 1H); 2.08 (s, 3H). ESI-MS (cation): m/z calcd, 201.09 (M+H+); obs., 201.0. 

1H NMR (CDCl3, 300 MHz): δ 8.51 (d of m, J = 5.1 Hz, 1H); 7.65 (t of d, J = 7.8 Hz, 1.8 Hz, 1H); 7.48 (m, 2H); 7.31 (m, 3H); 7.17–7.26 (m, 2H); 5.85 (s, 1H); 1.94 (s, 3H).

2-(Pyridine-2-yl)propan-2-ol (PPO). Yield: 35%. 1H NMR (CDCl3, 300 MHz): δ 8.51 (d of m, J = 6.0 Hz, 1H); 7.71 (t of m, J = 7.8 Hz, 1H); 7.32 (d of m, J = 9.0 Hz, 1H); 7.20 (t of m, J = 6.0 Hz, 1H); 5.18 (s, 1H); 1.78 (m, 2H); 1.51 (s, 3H); 1.19 (m, 6H); 0.82 (m, 6H).
Article

Journal of the American Chemical Society

from three separate experiments were pooled to determine average pKₐ values.

In addition, 25 μM solutions of 1:1 [Rh(chrysi)(phen)(PO)] ::DNA, [Rh(chrysi)(phen)(PPE)] ::DNA, [Rh(chrysi)(phen)(PPO)] ::DNA or [Rh(DHPA)(chrysi)] ::DNA (3 mL, in 100 mM NaCl, 20 mM NaPi, pH 7.1 buffer) were prepared and absorbed in a Cary 100 Bio UV–spectrophotometer. The DNA hairpin S‘-GGCCAGCTGGTCTTTTGCGTCATCCTGCCC-3′ (underline denotes the CC mismatch) was used.

Photocleavage Competition Titrations. The oligonucleotide S‘-GGC ATG CAG CTA TCA GTA GGA TTC TTC AGT ATG S‘ was 32P-labeled at the 5′-end by incubating DNA with [32P]-ATP and polynucleotide kinase (PNK) at 37 °C for 2 h, followed by purification using gel electrophoresis. A small amount of the labeled DNA (<1% of the total amount of DNA) was added to 2 μM unlabeled DNA and its corresponding unlabeled complement (with a CC mismatch incorporated at the underlined site) in 100 mM NaCl, 20 mM NaPi, pH 7.1 buffer. The duplex DNA was annealed by heating at 90 °C for 10 min and cooling slowly to ambient temperature over a period of 2 h. Solutions of non-photocleaving rhodium complex ranging from nanomolar to micromolar concentration as well as a 4 μM [Rh(bpy)(chrysi)] ::DNA solution were made in Milli-Q water. Annealed 2 μM DNA (10 μL), 4 μM [Rh(bpy)(chrysi)] ::DNA (5 μL), and 5 μL of non-photocleaving Rh solution at each concentration were mixed in a microcentrifuge tube and incubated at 37 °C for 10 min. A light control (ØRh), in which the DNA was mixed with 10 μL of water and irradiated, and a dark control (ØOh), in which the DNA was mixed with the highest concentration of rhodium complex without irradiation, were also prepared. The samples were then irradiated on an Orion (Darmstadt, Germany) 1000 W Hg/Xe solar simulator (340–440 nm) for 15 min. The samples were dried and electrophoresed on a 20% denaturing polyacrylamide gel. The gel was then exposed to a phosphor screen, and the relative amounts of DNA in each band were quantitated by phosphorimaging (ImageQuant).

Multiple Sequence Contexts. The oligonucleotide hairpins of the sequences S‘−GGCAAGCTGGTCTTTTGCGTCA TCCCGTTTGC (XY = CC, CA, CT, AA) were 32P-labeled at the 5′-end as described above. Samples of labeled DNA were combined with unlabeled carrier and annealed as described. Solutions of Δ- and Λ-[Rh(chrysi)(phen)(DPE)] ::DNA ranging from 0.5 μM to 2 mM as well as either 4 μM (CC and CT mismatches) or 20 μM (CA and AA mismatches) [Rh(bpy)(chrysi)] ::DNA solutions were made in Milli-Q water. Annealed 2 μM DNA (10 μL), 4 or 20 μM [Rh(bpy)(chrysi)] ::DNA (5 μL), and 5 μL of Δ- or Λ-[Rh(chrysi)(phen)(DPE)] ::DNA solution at each concentration was mixed in a microcentrifuge tube and incubated at 37 °C for 10 min. Samples were then irradiated and electrophoresed as described above.

Binding Constant Determination. The fraction of DNA cleaved in each lane on the gel (see Figure S5 for a typical autoradiogram) was normalized and plotted against the log of the concentration of rhodium complex. The data were fit to a sigmoidal curve using OriginPro 6.1 (Figure S6). The resulting midpoint value (i.e., the log of [rhodium complex] at the inflection point of the curve) was converted to units of concentration ([Rhµm]). The binding and dissociation constants of the non-photocleaving complex were determined by solving simultaneous equilibrium involving DNA, [Rh(bpy)(chrysi)] ::DNA, and the complex in question in Mathematica 6.0. The data from at least three photocleavage titrations were averaged for each metal complex to give an average binding affinity.

Covalent DNA Binding Assay. A 60 μM solution (250 μL) of the DNA hairpin S‘−GGCAAGCTGGTCTTTTGCGTCATCCCGTTTGC (underline denotes the CC mismatch) in either 100 mM NaCl, 20 mM NaPi, pH 7.1 or 100 mM NaCl, 5 mM glutathione (to mimic the reducing environment of the cell) was added to a 6 μM solution of [Rh(bpy)(chrysi)] ::DNA, [Rh(DHPA)(chrysi)] ::DNA, [Rh(chrysi)(phen)(PPE)] ::DNA, or H₂O (250 μL). The resulting solution was allowed to incubate at 37 °C for 30 min, followed by a 10 min incubation at 90 °C. A 3.0 M solution of NaOAc (50 μL) was added, followed by EtOH (1.5 mL) in order to precipitate the DNA. The resulting solution was vortexed and...
incubated on dry ice for 1.5 h, after which time it was spun at 14,000 rpm for 12 min. The supernatant was discarded, and the pellet dissolved in water (100 μL) and EtOH precipitated out again. The supernatant was discarded, and the pellet dissolved in water (500 μL). An electronic absorption (UV–vis) spectrum was then taken of the resulting solution on a Cary 100 Bio UV–vis spectrophotometer.

**Circular Dichroism Study of Δ/L-[Rh(chrysi)(phen)(DPE)]**

**Bound to Mismatched DNA.** 50 μM solutions of the DNA hairpin 5′-GGAGGCGATGGCTTTTTGCCATCCTGCTCC-3′ (underline denotes the CC mismatch) and Δ- and L-[Rh(chrysi)(phen)-(DPE)]2+ (200 μL in 100 mM NaCl, 20 mM NaP, pH 7.1 buffer) were prepared, and CD spectra were taken on an Aviv 62DS spectropolarimeter in a 1 mm path length cell. Each metal complex solution (100 μL) was then added to 100 μL of the DNA solution, and CD spectra were immediately recorded. After 30 min, additional CD spectra were recorded to confirm that no changes in the spectra occurred.

**Cell Culture.** HCT116N and HCT116O cells were grown in RPMI medium 1640 supplemented with 10% FBS; 2 mM L-glutamine; 0.1 mM penicillin; 100 μg/mL streptomycin; and 400 μg/mL Geneticin (G418). Cells were grown in tissue culture flasks (Corning Costar, Acton, MA) at 37 °C under 5% CO2 and humidified atmosphere.

**Cellular Proliferation ELISA.** HCT116N and HCT116O cells were plated in 96-well plates at 2000 cells/well and allowed 24 h to adhere. The cells were then incubated with either rhodium or the appropriate chemotherapeutic (cisplatin or MNNG) for the concentration and durations specified. After 24 h, the chemotherapeutic-containing media was replaced with fresh media, and the cells were grown for the remainder of the 72 h period. Cells were labeled with BrdU 24 h before analysis. The BrdU incorporation was quantified by antibody assay according to established procedures. Cellular proliferation was expressed as the ratio of the amount of BrdU incorporated by the treated cells to that of the untreated cells.

**MTT Cytotoxicity Assay.** Cytotoxicity assays were performed as described in the literature. HCT116N and HCT116O cells were plated in 96-well plates at 50,000 cells/well and incubated with rhodium for the durations specified. After rhodium incubation, cells were labeled with MTT for 4 h at 37 °C under 5% CO2 and humidified atmosphere. The resulting formazan crystals were dissolved by solubilizing reagent purchased from Roche according to the manufacturer’s instructions. The dissolved formazan was quantified by absorbance at 570 nm. A standard curve can be constructed, and the pK values of the compounds can be determined from the in vivo absorbance changes which occur as the pH of a rhodium complex solution is titrated can be used for the determination of the pK values of the compounds. As the pH of the solution increases from 4.5 to 11, the band centered near 600 nm (which corresponds to a charge-transfer transition between the rhod and the chrysi ligand) undergoes a blue shift (Figures S3 and S4). When the absorbance values at the initial maximum are plotted as a function of pH, a titration curve can be constructed, and the pK value of each metal complex can be determined from the inflection point of the curve. The pK values for these complexes are given in Table 1. These values reflect differences in equilibria constants of almost 2 orders of magnitude, likely due to the negative charge of the alkoxide ligands as compared to HDPA and bpy.

All three crystallographically characterized compounds are synthesized as a mixture of two diastereomers (see Experimental Section), but only the diastereomers of [Rh(chrysi)-(phen)(DPE)]2+ were resolvable via HPLC. The enantiomers

### RESULTS

**Synthesis and Characterization of Compounds.** Single crystals of [Rh(chrysi)(phen)(DPE)]Cl2 were grown from a vapor diffusion of diethyl ether into a concentrated solution of the complex in ethanol. The solved structure revealed the DPE ligand to coordinate via the oxygen instead of the second pyridine nitrogen. In order to assess the generality of this coordination environment and to determine if the solid-state structure of [Rh(chrysi)(phen)(DPE)]Cl2 is the same as its solution structure, we synthesized a phenyl (PPE) derivative and a methyl (PPO) derivative (Figure 1). Both ligands are notable in their lack of a second nitrogen to coordinate to the rhodium center. These new compounds can be synthesized via analogous methods and in reasonable yields. Single crystals grown of both compounds confirmed the generality of this unusual ligand coordination (Figures S3 and S4).

These compounds were also designed to ascertain the importance of both the ligand coordination environment (the presence of a Rh–O bond) and the bulky “dangling” pyridine group with regards to the enhanced potency and cell-selective activity of the parent compound. An additional compound with a greasy hexyl group appended to this ligand scaffold was also synthesized to assess the effects of lipophilicity on the biological activity of this family of compounds.

The acidity constants of the immine protons in [Rh(chrysi)-(phen)(DPE)]2+, [Rh(chrysi)(phen)(PPE)]2+, and [Rh(chrysi)(phen)(PPO)]2+ as compared to [Rh(HDPA)2-(chrysi)]+ and [Rh(bpy)3(chrysi)]3+ were determined by pH spectroscopic titrations. It has previously been demonstrated that the visible absorbance changes which occur as the pH of a rhodium complex solution is titrated can be used for the determination of the pK values of the compounds. As the pH of the solution increases from 4.5 to 11, the band centered near 440 nm (which corresponds to a charge-transfer transition between the Rh center and the chrysi ligand) undergoes a blue shift (Figures S3 and S4). When the absorbance values at the initial maximum are plotted as a function of pH, a titration curve can be constructed, and the pK values of each metal complex can be determined from the inflection point of the curve. The pK values for these complexes are given in Table 1. These values reflect differences in equilibrium constants of almost 2 orders of magnitude, likely due to the negative charge of the alkoxide ligands as compared to HDPA and bpy.

All three crystallographically characterized compounds are synthesized as a mixture of two diastereomers (see Experimental Section), but only the diastereomers of [Rh(chrysi)-(phen)(DPE)]2+ were resolvable via HPLC. The enantiomers

### Table 1. pK Values for All Compounds As Determined by Spectrophotometric Titration

| compound | pKa |
|----------|-----|
| [Rh(bpy)3(chrysi)]3+ | 6.9 ± 0.2 |
| [Rh(HDPA)2(chrysi)]2+ | 7.0 ± 0.5 |
| [Rh(chrysi)(phen)(DPE)]2+ | 8.7 ± 0.2 |
| [Rh(chrysi)(phen)(PPE)]2+ | 8.9 ± 0.4 |
| [Rh(chrysi)(phen)(PPO)]2+ | 8.3 ± 0.3 |

*Titrations were performed at ambient temperature in 0.1 M NaCl solutions. Reported errors were found from repeated trials. [Rh(bpy)3(chrysi)]3+ pK matches with the previously reported value of 5.2 ± 0.2. All compounds were used as racemic mixtures.*
of [Rh(chrysi)(phen)(DPE)]²⁺ were separated and characterized via CD spectroscopy (Figure S11). HPLC analysis of the purified fractions confirmed >95% ee of the Δ isomer and ∼90% ee of the Λ isomer (data not shown). These enantiomers are stable in aqueous solution for up to 1 month; no interconversion of the enantiomers is observed in either neutral buffer or buffer with 5 mM glutathione.

Binding of Complexes to Oligonucleotides Containing Single Base Mismatches. To ascertain the protonation states of the chrysi ligands of [Rh(chrysi)(phen)(DPE)]²⁺, [Rh(chrysi)(phen)(PPE)]²⁺, [Rh(chrysi)(phen)(PPO)]²⁺, [Rh(HDPA)₂(chrysi)]³⁺, and [Rh(bpy)₂(chrysi)]³⁺ upon mismatched DNA binding, mismatched DNA was added to all compounds in a 1:1 ratio and absorption spectra recorded. As can be seen in Figure 3, [Rh(chrysi)(phen)(DPE)]²⁺ binds to mismatched DNA with retention of both immine protons. Due to the extent of hypochromicity and red-shifting of the charge-transfer band, it is clear that the complex binds strongly to the mismatched DNA. In contrast, the chrysi ligand of [Rh(bpy)₂(chrysi)]³⁺ is deprotonated upon mismatched DNA binding. Again, hypochromicity and red-shifting of the CT band show a strong binding of the complex to mismatched DNA. This result is consistent with the various crystal structures of [Rh(bpy)₂(chrysi)]³⁺ bound to different DNA mismatches. The other Rh–O containing compounds [Rh(chrysi)(phen)(PPE)]²⁺ and [Rh(chrysi)(phen)(PPO)]²⁺ were also found to retain both immine protons upon DNA binding (Figure S12), while [Rh(HDPA)₂(chrysi)]³⁺ appears to be a mixture of protonated and deprotonated species when bound to mismatched DNA (Figure S12).

The new family of complexes does not promote DNA cleavage upon irradiation, and, as such, their binding affinities were determined through binding competition titrations with 1 μM rac-[Rh(bpy)₂(chrysi)]³⁺, which does cleave DNA upon irradiation. Titrations were performed with a 36-mer DNA duplex containing a CC mismatch (underlined): 3′-GGCAGGCAATGCTTTTTGCGATCCCTGCC-3′ (underline denotes the CC mismatch) in 100 mM NaCl, 20 mM NaPi, pH 7.1 buffer. The absorption spectra of the species retaining the immine protons are shown in green, those of the deprotonated species are in red, and those of the compounds in 100 mM NaCl, 20 mM NaPi pH 7.1 buffer with no DNA are shown in purple.

Figure 3. Top: pH titration of [Rh(chrysi)(phen)(DPE)]²⁺. Shown are absorption spectra of a 25 μM solution of [Rh(chrysi)(phen)(DPE)]²⁺ as the pH changes from 5.6 (red) to 10.2 (purple). The black arrows exhibit the direction in which the various bands change as the pH increases. (Inset) The absorbance at 440 nm was plotted as a function of pH and fit to a sigmoidal curve. The pKₐ was determined from the inflection point of this curve. Bottom: Absorption spectra of [Rh(chrysi)(phen)(DPE)]²⁺ (left) and [Rh(bpy)₂(chrysi)]³⁺ (right) bound to mismatched DNA. Shown in blue are absorption spectra of 25 μM solutions of [Rh(chrysi)(phen)(DPE)]²⁺ and [Rh(bpy)₂(chrysi)]³⁺ with 25 μM of the DNA hairpin 5′-GGCAGGCAATGCTTTTTGCGATCCCTGCC-3′ (underline denotes the CC mismatch) in 100 mM NaCl, 20 mM NaPi, pH 7.1 buffer. The absorbance at 440 nm was plotted as a function of pH and fit to a sigmoidal curve. The pKₐ was determined from the inflection point of this curve.
Mismatched Sites

...non-sequence specificity with the thermodynamic destabilization of the mismatch. 28 mismatch). Binding competition gels between both [Rh(bpy)2(chrysi)]3+, binding a...metalloinsertor-mismatched DNA complexes are distinct from can be seen in Figure 4, the CD spectra of the two enantiomers before and after addition to mismatched DNA. As occurs upon DNA binding, CD spectra were taken of the two enantiomer. This correlation is due to the unique binding mode of...possibility of non-mismatch-specific destabilization (1.1 kcal/mol) of the DPE complex at a variety of DNA mismatches were determined. It has been reported that the mismatch-specific DNA binding affinities of ∆-[Rh(bpy)2(chrysi)]3+ correlate with the thermodynamic destabilization of the mismatch. This correlation is due to the unique binding mode of metalloinsertion where the mismatched base pair is completely ejected from the double helix upon metal complex binding. Therefore, four different DNA hairpins of the form 5′-GGCAGTXXCTGGCTTTTTGCC-ACTGCC-3′ (XY = CC, CT, CA, or AA, underline denotes the mismatch) in a competition assay through photocleavage by [Rh(bpy)2(chrysi)]3+. Binding constants all have standard errors within 10%. "Mismatch thermodynamic values found from ref 29.

Due to the drastic differences in mismatched DNA binding characterization between [Rh(chrysi)(phen)(DPE)]2+ and [Rh(bpy)2(chrysi)]3+, binding affinities of both enantiomers of the DPE complex at a variety of DNA mismatches were determined. It has been reported that the mismatch-specific DNA binding affinities of ∆-[Rh(bpy)2(chrysi)]3+ correlate with the thermodynamic destabilization of the mismatch. 28 This correlation is due to the unique binding mode of metalloinsertion where the mismatched base pair is completely ejected from the double helix upon metal complex binding. Therefore, four different DNA hairpins of the form 5′-GGCAGTXXCTGGCTTTTTGCC-ACTGCC-3′ (XY = CC, CT, CA, or AA, underline denotes the mismatch) in a competition assay through photocleavage by [Rh(bpy)2(chrysi)]3+. Binding constants all have standard errors within 10%. "Mismatch thermodynamic values found from ref 29.

Table 2. Thermodynamic Binding Constants of ∆- and Λ-[Rh(chrysi)(phen)(DPE)]2+ and ∆-[Rh(bpy)2(chrysi)]3+ at Varied Mismatched Sites

| mismatch | ∆ (× 10^6 M−1) | Λ (× 10^6 M−1) | [Rh(bpy)2(chrysi)]3+ (× 10^6 M−1) | destabilization (kcal/mol) |
|----------|---------------|---------------|---------------------------------|---------------------------|
| CC       | 1.1           | 1.1           | 2.4                             | 2.15                      |
| CT       | 0.55          | 1.0           | 4.6                             | 2.0                       |
| CA       | 0.47          | 2.4           | 2.0                             | 1.4                       |
| AA       | 0.23          | 3.5           | 1.6                             | 0.8                       |

"DNA binding affinities were measured in 100 mM NaCl, 20 mM NaP, pH 7.1 buffer on the 29-mer hairpins 5′-GGCAGTXXCTGGCTTTTTGCC-ACTGCC-3′ (XY = CC, CT, CA, or AA, underline denotes the mismatch) in a competition assay through photocleavage by [Rh(bpy)2(chrysi)]3+. Binding constants all have standard errors within 10%. "Mismatch thermodynamic values found from ref 29.

Figure 4. CD spectra of ∆- and Λ-[Rh(chrysi)(phen)(DPE)]2+ bound to mismatched DNA. Shown are spectra of 25 μM solutions of ∆- and Λ-[Rh(chrysi)(phen)(DPE)]2+ in 100 mM NaCl, 20 mM NaP, pH 7.1 buffer bound to the DNA hairpin 5′-GGCAGGCGATGCGCTTTTTGCC-CATGCCCTGCC-3′ (underline denotes the CC mismatch), and the DNA hairpin alone (Δ in blue, Λ in red, DNA alone in gray).

Inhibition of Cellular Proliferation using an Enzyme-Linked Immunosorbent Assay (ELISA). An ELISA for DNA synthesis was used to quantify the effects of the new family of metalloinsertors on the proliferation of HCT116N cells (MMR-proficient) and HCT116O cells (MMR-deficient) (Figure 5). The compound [Rh(HDPA)2(chrysi)]3+ was included as a control with which to compare the potencies and selectivities of the new compounds. Cisplatin and methylmethotrexate (MMNG) were also included as prototypical, FDA-approved chemotherapeutic agents that exhibit decreased effectiveness against MMR-deficient cancer.
Incubations were performed for 24 h, after which time the medium containing the chemotherapeutic was replaced with fresh medium, and the cells were grown for the remainder of the 72 h period. The extent of cellular proliferation is expressed as the ratio of BrdU incorporated by the treated cells as compared to untreated controls. We define differential inhibition as the difference in %BrdU incorporation between the HCT116N and HCT116O cells. The results are shown in Figure 5. Clearly, the new family of complexes has significantly enhanced potency as compared to the earlier generation metalloinsertor; concentrations required for optimal differential activity are reduced from 10 μM for [Rh(HDPA)₂(chrysi)]³⁺, 1 μM for [Rh(chrysi)(phen)-(PPE)]²⁺, and 300 nM for [Rh(chrysi)(phen)(PPO)]²⁺. These compounds are also more potent than the FDA-approved chemotherapeutics in these assay conditions, which require 4 and 6 μM for optimal biological activity of MNNG and cisplatin, respectively. In addition, the enhanced cell-selectivity that was observed previously with [Rh(chrysi)(phen)(DPE)]²⁺ is conserved across the entire family. At their optimal concentrations, their differential inhibitions are 55 ± 2%, 53 ± 7%, and 62 ± 2% for the DPE, PPE, and PPO derivatives, respectively. Note that any cell selectivity by cisplatin or MNNG favors the MMR-proficient cells. This is Figure 5. Inhibitory effects of rac-[Rh(chrysi)(phen)(DPE)]²⁺, rac-[Rh(chrysi)(phen)(PPE)]²⁺, rac-[Rh(chrysi)(phen)(PPO)]²⁺, rac-[Rh(HDPA)₂(chrysi)]³⁺, MNNG, and cisplatin. Shown are plots of BrdU incorporation (a measure of DNA synthesis and therefore cellular proliferation) normalized to the BrdU incorporation of untreated cells as a function of rhodium concentration. Standard error bars for five trials are shown.
characteristic of the DNA-binding therapeutics and leads to significant buildup of drug resistance in the clinic. The family of metalloinsertors instead shows activity preferentially in the MMR-deficient cells. This selectivity is unique to all active metalloinsertors, but this new generation of complexes exhibits levels of selectivity and potency previously unseen.

**MTT Cytotoxicity Assay.** The cytotoxic effects of all complexes were determined by MTT assay. Briefly, reduction of the MTT reagent by metabolically active cells leads to the production of formazan, which can then be dissolved in acidified SDS to produce a characteristic absorbance at 570 nm. Thus, this absorbance reflects the amount of metabolically active cells in each sample. HCT116N and HCT116O cells were plated and treated with the various rhodium complexes at the concentrations indicated in Figure 6 for 72 h. Percent viability is defined as the ratio of the amount of formazan in the treated cells to that in the untreated cells, and differential cytotoxicity is defined as the difference between the percent viabilities of the two cell lines. The results are shown in Figure 6. All four compounds in this new family display differential cytotoxicity in excess of 50%, and three compounds exhibit maximal activity at nanomolar concentrations. Specifically, the differential cytotoxicities and optimal concentrations of [Rh(chrysi)(phen)(DPE)]^{2+}, [Rh(chrysi)(phen)(PPE)]^{2+}, [Rh(chrysi)(phen)(PPO)]^{2+}, and [Rh(chrysi)(phen)(PyOctanol)]^{2+} are 76 ± 2% at 6 μM, 66 ± 2% at 720 nM, 66 ± 3% at 320 nM, and 55 ± 3% at 480 nM, respectively. This is an increase in cytotoxic potency of almost 2 orders of magnitude as compared to [Rh(HDPA)_{2}(chrysi)]^{3+} (25 μM required for optimal cytotoxicity). Moreover, this is the only instance of a metalloinsertor with a lipophilic ancillary ligand that retains the cell-selective activity unique to our compounds.

The cell-selective cytotoxicities of the two enantiomers of [Rh(chrysi)(phen)(DPE)]^{2+} were also assessed (Figure S14). Just as both enantiomers bind with equal affinity to DNA mismatches, both enantiomers display similar cell-selectivity; their optimal differential cytotoxicities are 78 ± 1% and 75 ± 2% for Δ and Λ, respectively, although the Λ enantiomer requires a higher concentration. This is again in direct contrast to [Rh(bpy)_{2}(chrysi)]^{3+}, where only the Δ isomer displays differential biological activity.

**ICP-MS Assay for Whole-Cell Rhodium Levels.** HCT116O and HCT116N cells were treated with each rhodium complex at the concentrations indicated in Figure S15 for 24 h. Whole cell lysates were subsequently analyzed for rhodium levels by ICP-MS and normalized to protein content (Figure S15). These Rh complex concentrations correspond to those necessary for optimal biological activity in the 24 h ELISA experiment for the four different complexes. Therefore, the intracellular rhodium concentrations in this experiment reflect the amount of rhodium in the cell that is required for an optimal biological response. It is striking that the new family of compounds requires significantly less intracellular rhodium to elicit a biological response than the prototypical [Rh(HDPA)_{2}(chrysi)]^{3+} compound; specifically, the new compounds exhibit comparable biological activity to [Rh(HDPA)_{2}(chrysi)]^{3+} with only 20 ± 2% ([Rh(chrysi)(phen)(DPE)]^{2+}), 15 ± 5% ([Rh(chrysi)(phen)(PPE)]^{2+}), or 13 ± 2% ([Rh(chrysi)(phen)(PPO)]^{2+}) of the amount of intracellular rhodium.

**Mode of Cell Death.** The mode of cell death upon rhodium treatment was characterized through a dye-exclusion
Flow cytometry assay. The assay differentiates between live cells, dead cells, and cells undergoing apoptosis or necrosis through concurrent staining with propidium iodide (a dead-cell-permeable dye) and YO-PRO-1 (an apoptotic-cell-permeable dye). By plotting the fluorescence of the YO-PRO-1 channel against the PI channel, a pattern emerges. Healthy cells are seen in the lower lefthand corner of the plot as they incorporate neither dye. Apoptotic cells exhibit higher YO-PRO-1 fluorescence but still exclude propidium iodide, placing them in the upper lefthand quadrant of the pattern. Conversely, necrotic cells admit propidium iodide but not YO-PRO-1 and are thus in the lower righthand quadrant. Dead cells admit both dyes and are therefore seen in the upper righthand quadrant of the image. Upon flow cytometry analysis, cells can be classified as live, apoptotic, necrotic, or dead by defining regions in the fluorescence plane corresponding to each category.

The HCT116N and HCT116O cell lines were incubated with 0–0.5 μM of [Rh(chrysi)(phen)(PPO)]2+ for 72 h. After harvesting the cells and staining with both PI and YO-PRO-1, the cells were analyzed by flow cytometry to obtain raw fluorescence data. Representative data for 200 nM rhodium treatment for 72 h are shown in Figure 7. YO-PRO-1 fluorescence is shown on the y-axis, and PI fluorescence is shown on the x-axis. The raw data were analyzed by gating the fluorescence events into one of four categories. Figure 7 also shows histograms of live, apoptotic, necrotic, and dead cells for the HCT116N and HCT116O cell lines based on the flow cytometry. Rhodium treatment was either 0.2 or 0.5 μM [Rh(chrysi)(phen)(PPO)]2+ for 72 h. As with [Rh(HDPA)2chrysi][Rh(chrysi)(phen)(PPO)]2+ treatment induces necrosis preferentially in the MMR-deficient HCT116O cell line; the number of necrotic cells increases from 1.2 ± 0.1% to 13 ± 2% after treatment with 0.2 μM [Rh(chrysi)(phen)(PPO)]2+. There is no significant change in the percentage of cells in the apoptotic region in either cell line following metalloinsertor treatment (26 ± 7% vs 25 ± 7% for the HCT116N cell line, and 10 ± 6% vs 17 ± 7% for the HCT116O cell line). The effect of rhodium treatment is significantly more pronounced in the MMR-deficient HCT116O cell line, in which live cells drop from 82 ± 7% to 28 ± 6% after treatment with 0.2 μM [Rh(chrysi)(phen)(PPO)]2+ versus the MMR-proficient HCT116N cell line, which shows no decrease in live cells (57 ± 9% versus 57 ± 7%) after treatment with 0.2 μM [Rh(chrysi)(phen)(PPO)]2+.

**DISCUSSION**

A new family of rhodium complexes containing Rh–O coordination have been prepared, and all show higher potency and selectivity for MMR-deficient cells compared to earlier rhodium metalloinsertors. The DPE ligand was originally designed to coordinate to the Rh center via the two pyridine rings, as per previously synthesized metalloinsertors. The solid-state structure of [Rh(chrysi)(phen)(DPE)]2+ revealed the true coordination to include an axial Rh–O bond. The driving force for this ligand coordination may be the formation of a five-membered ring, as opposed to the six-membered ring that would form if the second pyridine ring coordinated. This family of complexes offers new possibilities for binding DNA mismatches and for providing potent targets for cellular processing.

**Characterization in Solution and Binding to Mismatched DNA.** Spectrophotometric titrations reveal that the acidity of the chrysi imeine proton of the new complexes...

Figure 7. Flow cytometry assay of cell death mechanism. (Top) HCT116N and HCT116O cells were treated with 0.2 μM [Rh(chrysi)(phen)(PPO)]2+ for 72 h. The color scale represents the number of cells, with blue indicating fewer cells at a given pair of fluorescence levels, and orange representing a greater number of cells at a given pair of fluorescence levels. Rhodium treatment causes cells to move away from the origin, along the necrotic pathway (lower branch of pattern). The effect is more pronounced in the HCT116O cell line. (Bottom) HCT116N and HCT116O cells were treated with 0.2 or 0.5 μM [Rh(chrysi)(phen)(PPO)]2+ for 72 h. Rhodium treatment causes a sharp decrease in the live population of the HCT116O cell line with a corresponding increase in the necrotic and dead cell populations. Less of an effect is seen in the HCT116N cell line. Thus, these data are consistent with [Rh(chrysi)(phen)(PPO)]2+ preferentially inducing necrosis in the MMR-deficient HCT116O cell line.
(pK\textsubscript{a}'s of 8.3 to 8.9) vary significantly from that of [Rh(bpy)\textsubscript{2}(chrysi)]\textsuperscript{3+} (pK\textsubscript{a} of 5.2\textsuperscript{17} and [Rh(HDPA)\textsubscript{2}-(chrysi)]\textsuperscript{3+} (pK\textsubscript{a} of 7.0). This difference is most likely due to the negative charge on the DPE ligand; a more basic environment is required to deprotonate the 2+ \([\text{Rh(chrysi)-(phen)(DPE)}]\textsuperscript{2+} species than the 3+ \([\text{Rh(HDPA)_2(chrysi)}]\textsuperscript{3+} species. Furthermore, in the case of \([\text{Rh(bpy)}\textsubscript{2}(chrysi)]\textsuperscript{3+}, the chrysi immine proton must be deprotonated in order for the molecule to bind to mismatched DNA.\textsuperscript{10,11} When both immine protons are retained, the chrysi ligand is not planar (Figures 2 and 8) due to steric clashing, which, effectively prevents full \(\pi\)-stacking with the base pairs adjacent to the mismatched site upon DNA binding. Despite this fact, the entire family of complexes appears to bind to mismatched DNA without deprotonation (Figures 3 and S12). Additionally, substantial hypochromicity is observed upon DNA binding, confirming that there must be significant \(\pi\)-stacking between the DNA and the chrysi ligand. These observations suggest a different conformation for mismatch binding with this new family of complexes as compared to \([\text{Rh(bpy)}\textsubscript{2}(chrysi)]\textsuperscript{3+}.

We also explored the possibility of covalent binding through displacement of the Rh–O bond and substitution of a DNA base as a ligand. The ensuing covalent lesion could be a potent target for the machinery of the cell.\textsuperscript{6} However, even under an extremely reducing environment (5 mM glutathione), we find no evidence of covalent binding of the complex to DNA.

In order to further characterize the compounds and their interactions with DNA, the enantiomers of \([\text{Rh(chrysi)-(phen)}(DPE)]\textsuperscript{2+}\) were separated by HPLC. In the case of a labile Rh–O bond, racemization of the enantiomers would be expected to occur over time.\textsuperscript{13} However, samples of both enantiomers in aqueous solution in light exhibited no racemization over a month, as confirmed by chiral HPLC and CD. Furthermore, the two enantiomers do not racemize upon DNA binding (Figure 4), and, in fact, exhibit distinct CD spectra when bound to DNA, providing direct evidence that both enantiomers are stable and bind individually to mismatches.

Do the complexes bind to mismatched DNA through metalloinsertion? Both the \(\Delta\) and \(\Lambda\) isomers of \([\text{Rh(chrysi)-(phen)(DPE)}]\textsuperscript{2+} bind with equally high specificity for mismatched DNA and with similar binding affinities. For \(\Delta\)\textsuperscript{\text{-}}[\text{Rh(chrysi)(phen)(DPE)}]\textsuperscript{2+} we also see a correlation between binding affinity and destabilization of the mismatch, and this provides strong support for binding through metalloinsertion for the \(\Delta\)-isomers. The fact that the DNA mismatch binding affinities of \(\Lambda\text{-}[\text{Rh(chrysi)(phen)(DPE)}]\textsuperscript{2+} do not correlate with the destabilization of the mismatch is surprising. It may be the case that buckling by the chrysi ligand coupled with steric clashes by the \(\Lambda\)-isomer with the helix means that full insertion may not occur, and instead there may be some twisting of the complex within the site. More structural characterizations is clearly required here.

**Biological Effects of the Complexes in Cells.** Most important is the high biological activity of the new generation of complexes coupled with their high selectivity for MMR-deficient cells. As can be seen from Figures 5 and 6, all four complexes exhibit the MMR-deficient cell-selective activity that is unique to rhodium metalloinsertors. Indeed, appending additional steric bulk off the back of the complexes does not interfere with the cellular response to the rhodium-DNA lesion associated with mismatch binding. The fact that \([\text{Rh(chrysi)-(phen)(PyOctanol)}]\textsuperscript{2+} retains its cell selectivity is also surprising given our recent results that the more lipophilic metalloinsertors localize to the mitochondria, which in effect abolishes their cell selectivity.\textsuperscript{18} One possibility is that the ancillary PyOctanol ligand dissociates either prior to or following cellular uptake. Again, our results show the lack of racemization of the \([\text{Rh(chrysi)(phen)(DPE)}]\textsuperscript{2+} over a month in a reducing aqueous environment argue against that explanation. Both \(\Delta\) and \(\Lambda\)-[Rh(chrysi)(phen)(DPE)]\textsuperscript{2+} display comparable cell-selective activity in the MTT assay. This result implies similar Rh-DNA lesions being formed for the two enantiomers; if the enantiomers were binding to DNA using markedly different binding modes, their biological activities would vary greatly.

We also assessed cellular uptake of the family and compared them to that of \([\text{Rh(HDPA)_2chrysi}]\textsuperscript{3+}. The new family of complexes require from 7.5- to 5-fold less intracellular rhodium as compared to \([\text{Rh(HDPA)_2chrysi}]\textsuperscript{3+} to evoke the same cellular response. This may be an indication that the Rh-DNA lesion being formed is more readily recognized by the cellular machinery, and thus fewer lesions are required for cytotoxicity. Furthermore, the three complexes with Rh–O bonds exhibit similar intracellular rhodium concentrations; they vary <1.5-fold from each other. This is despite a 10-fold difference in the rhodium concentration of the media between \([\text{Rh(chrysi)-(phen)(DPE)}]\textsuperscript{2+} and \([\text{Rh(chrysi)(phen)(PPO)}]\textsuperscript{2+}. This clearly demonstrates that the latter compound has more efficient uptake than the parental DPE compound.

Finally, we evaluated the mode of cell death caused by treatment of HCT116 cells with the new complex \([\text{Rh(chrysi)-} (DPE)]\textsuperscript{2+}\) and compared them to that of \([\text{Rh(HDPA)_2chrysi}]\textsuperscript{3+}. The new family of complexes shows a distinct trend in the mode of cell death. As seen from Figures 9 and S13, all four complexes show similar intracellular rhodium concentrations between \([\text{Rh(chrysi)-(phen)(DPE)}]\textsuperscript{2+} and \([\text{Rh(chrysi)-} (phen)(PPO)}\textsuperscript{2+}. This is consistent with the previous results showing that the Rh-DNA lesions being formed are more readily recognized by the cellular machinery, and thus fewer lesions are required for cytotoxicity.
(phen)(PPO)]^{2+} as a representative member of the new family. The admission of the dead-cell stain propidium iodide by the HCT116 cell lines upon rhodium treatment reveals that cell death proceeds through a necrotic, rather than apoptotic pathway, similar to [Rh(HDPA)chrysi]^{3+} treatment (Figure 7). If there is a different Rh-DNA lesion being formed by the new family of complexes, then it is not different enough to evoke a significantly altered global cellular response. Certainly, the enhanced potency and selectivity of these new complexes make them suitable candidates for the next step in chemotherapeutic development.

**Models for DNA Insertion by the Complexes.** Given the potency of the complexes, it becomes important to explore how they might be oriented on the DNA helix to provide a target for cellular responses. Figure 8 compares two different proposed models of Δ-[Rh(phen)(chrysi)(phen)]^{22} bound to a mismatched site in DNA. Preserving the DNA conformation from the crystal structure of [Rh(bpy)_{2}chrysi]^{3+} bound to an AC mismatch,10 in one model, we simply overlaid the chrysi ligand and the adjacent base pairs (shown in green). This steric clash is partially alleviated when the DPE complex is exchanged for the PPO complex and exacerbated when exchanged for Δ-[Rh(bpy)_{2}phen][chrysi]^{3+} when bound to mismatched DNA. In the other model, Δ-[Rh(phen)(chrysi)(phen)]^{24} has been flipped and rotated to alleviate the steric clashing between the two ancillary ligands and the DNA, yet retain π-stacking between two rings of the chrysi ligand and the adjacent base pairs. Figure 8 shows that in the first model, there is the potential for significant steric clashing between the dangling pyridine group of [Rh(chrysi)(phen)]^{24} and the DNA backbone (shown in green). This steric clash is partially alleviated when the DPE complex is exchanged for the PPO complex and exacerbated when exchanged for Δ-[Rh(chrysi)(phen)]^{24} (not shown). Given the similarity in binding affinities of the various complexes, it is clear that this cannot be the correct binding conformation for this new family. In the second model, there is no steric clashing between the ancillary ligands and the DNA. This model, in which π-stacking between the chrysi ligand and the base pairs adjacent to the mismatch is reduced in order to circumvent this steric clashing, is consistent with all our results. Due to the presence of both chrysi imine protons upon DNA binding, it is not possible for the chrysi ligand to π-stack with the adjacent base pairs using all four rings. This in turn allows for more flexibility in the placement of the metal complex in the minor groove, thus permitting positioning of the complexes in the minor groove without any steric clashing. This reduced stacking may account for the ∼5-fold lower binding affinity of Δ-[Rh(phen)(chrysi)(phen)]^{24} for mismatched DNA as compared to Δ-[Rh(bpy)_{2}phen(chrysi)]^{24}.

It is also important to consider the orientation of the ejected bases in the mismatch-bound complexes. Indeed these bases may be the target for the high cellular response. Significant differences in positioning of the ejected bases are evident when we compare the crystal structures of [Rh(bpy)_{2}chrysi]^{3+} and [Ru(bpy)_{2}(dpz)]^{2+} bound to mismatched DNA through metalloinsertion.36 For the Ru complex, the ejected bases are pulled into the minor groove so as to interact with the ancillary ligands of the metalloinsertor. As illustrated in Figure 8, positioning the complex in a more twisted configuration as a result of the chrysi buckling actually orients the complex closer to the wall of the minor groove; perhaps the ejected bases further stabilize that positioning similar to what is seen for the Ru complex. Understanding these structural aspects will require further structural characterization, however.

**CONCLUSIONS**

Here we have described a family of rhodium metalloinsertors with a new coordination containing a Rh–O bond axial to the inserting chrysi ligand. This new ligand coordination has been found to lead to enhanced potency and selectivity toward MMR-deficient cancer cells. Indeed, the new complexes appear to be significantly more selective and also more potent than classic chemotherapeutics.30 The complexes share a higher pK_a of the chrysi ligand, leading to the absence of imine deprotonation and thus the buckling of the inserting ligand within the mismatched site. For many years, the focus of bioinorganic chemists has been on the preparation of more potent analogues of cisplatin that bind covalently to DNA bases.3,4 However, focus has recently shifted toward the preparation of chemotherapeutics that are more selective than cisplatin owing to design strategies where the complex interacts with a specific biological target found prominently in cancer cells.7 This new generation of metalloinsertors provides for non-covalent binding to a specific cellular target, DNA mismatches, with high potency and selectively in cells deficient in MMR. This new generation of complexes thus provides an exciting new platform for therapeutic development.

**ASSOCIATED CONTENT**

Supporting Information

Crystallographic data, representative binding affinity determination, pH titrations, enantiomeric characterization, further DNA binding characterization, and cytotoxicity of the two enantiomers as well as cellular uptake data. This material is available free of charge via the Internet at http://pubs.acs.org.

**AUTHOR INFORMATION**

**Corresponding Author**

jkbarton@caltech.edu

**Notes**

The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**

Financial support for this work from the NIH (GM33309) is gratefully acknowledged. We also thank the National Science Foundation for a Graduate Research Fellowship to A.C.K. This project benefitted from the use of instrumentation made available by the Caltech Environmental Analysis Center. Lawrence Henling and Dr. Michael K. Takase (Caltech) are gratefully acknowledged for expertise in flow cytometry.

**REFERENCES**

(1) Zhang, C. X.; Lippard, S. J. *Carr. Opin. Chem. Biol.* 2003, 7, 481–489.

(2) Mansour, V. H.; Rosenberg, B.; Vancamp, L.; Trosko, J. E. *Nature* 1969, 222, 385–386.

(3) Wheat, N. J.; Walker, S.; Craig, G. E.; Oun, R. *Dalton Trans.* 2010, 39, 8113–8127.

(4) Kelland, L. R.; Sharp, S. Y.; O'Neill, C. F.; Raynaud, F. I.; Beale, P. J.; Judson, I. R. J. *Inorg. Biochem.* 1999, 77, 111–115.

(5) Boulikas, T.; Vougiouka, M. *Oncol. Rep.* 2004, 11, 559–595.

(6) Jamieson, E. R.; Lippard, S. J. *Chem. Rev.* 1999, 99, 2467–2498.
Weidmann, A. G.; Komor, A. C.; Barton, J. K. *Comment. Inorg. Chem.* 2014, 34, 1–10.

Jackson, B. A.; Barton, J. K. *J. Am. Chem. Soc.* 1997, 119, 12986–12987.

Jackson, B. A.; Alekseyev, V. Y.; Barton, J. K. *Biochemistry* 1999, 38, 4655–4662.

Pierre, V. C.; Kaiser, J. T.; Barton, J. K. *Proc. Natl. Acad. Sci. U.S.A.* 2007, 104, 429–434.

Zeglis, B. M.; Pierre, V. C.; Kaiser, J. T.; Barton, J. K. *Biochemistry* 2009, 48, 4247–4253.

Loeb, L. A. *Cancer Res.* 2001, 61, 3230–3239.

Jackson, B. A.; Skandalis, A.; Ganesh, A.; Groden, J.; Meuth, M. *Proc. Natl. Acad. Sci. U.S.A.* 1994, 91, 6319–6323.

Iyer, R. R.; Pluciennik, A.; Burdett, V.; Modrich, P. L. *Chem. Rev.* 2006, 106, 302–323.

Carethers, J. M.; Hawn, M. T.; Chauhan, D. P.; Luce, M. C.; Marra, G.; Koi, M.; Boland, C. R. *J. Clin. Invest.* 1996, 98, 199–206.

Hart, J. R.; Glebov, O.; Ernst, R. J.; Kirsch, I. R.; Barton, J. K. *Proc. Natl. Acad. Sci. U.S.A.* 2006, 103, 15359–15363.

Ernst, R. J.; Komor, A. C.; Barton, J. K. *Biochemistry* 2011, 50, 10919–10928.

Jackson, B. A.; Alekseyev, V. Y.; Barton, J. K. *Am. Chem. Soc.* 2012, 134, 19223–19233.

Ernst, R. J.; Song, H.; Barton, J. K. *J. Am. Chem. Soc.* 2009, 131, 2359–2366.

Jackson, B. A.; Henling, L. M.; Barton, J. K. *Inorg. Chem.* 1999, 38, 6218–6224.

Jackson, B. A.; Barton, J. K. *Biochemistry* 2000, 39, 6176–6182.

Peyret, N.; Seneviratne, A.; Allawi, H. T.; SantaLucia, J. *Biochemistry* 1999, 38, 3468–3477.

Mosmann, T. *J. Immunol. Methods* 1983, 65, 55–63.

Idziorek, T.; Estaquio, J.; DeBels, F.; Ameisen, J.-C. *J. Immunol. Methods* 1995, 185, 249–258.

Smith, P. K.; Krohn, R. I.; Hermanson, G. T.; Mallia, A. K.; Gartner, F. H.; Provenzano, M. D.; Fujimoto, E. K.; Goeke, N. M.; Olson, B. J.; Klenk, D. C. *Anal. Biochem.* 1985, 150, 76–85.

Jackson, B. A.; Henling, L. M.; Barton, J. K. *Inorg. Chem.* 1999, 38, 6218–6224.

Reitmar, A. H.; Risley, R.; Bristow, R. G.; Wilson, T.; Ganesh, A.; Jang, A.; Peacock, J.; Benchimol, S.; Hill, R. P. *Cancer Res.* 1997, 57, 3765–3771.

(30) Song, H.; Kaiser, J. T.; Barton, J. K. *Nat. Chem.* 2012, 4, 615–620.

